GlycoFlux™ Human SIGLEC2 Overexpression Jurkat Cell Line (CAT#: GLJF-0925-JF885)

Description	GlycoFlux™ human SIGLEC2 overexpression Jurkat cell line is a stable T-cell model engineered to overexpress SIGLEC2, a receptor that binds sialic acids, CD4, and protein phosphatases, regulating B-cell activation and signaling pathways. Found in endosomal compartments, SIGLEC2 dysregulation is associated with diffuse large B-cell lymphoma. This model offers a T-cell platform for studying lectin-mediated immune regulation and B-T cell communication in glycoimmune biology.
Product Type	Overexpression Cell Lines
Species	Human
Cell Morphology	Suspension-growing
Passage Ratio	1:3~1:5
Cell Line	Jurkat cell line
Primary Disease	T-cell acute lymphoblastic leukemia (T-ALL)
Lineage	T Lymphocyte
Lineage Subtype	T-cell acute lymphoblastic leukemia (T-ALL)

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	qPCR, Sanger Sequencing
Culture Medium	FBS & Penicillin/Streptomycin & RPMI
Application	Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	SIGLEC2
Full Name	Sialic Acid Binding Ig Like Lectin 2
Alternative Name	SIGLEC-2, CD22, Sialic Acid Binding Ig Like Lectin
Location	19q13.12
Gene ID	8778
Summary	The protein is predicted to have activities such as binding to CD4 receptors, protein phosphatases, and sialic acid. It plays a role in activating B cells, negatively regulating the B cell receptor signaling pathway, and controlling endocytosis. The protein is localized in early and recycling endosomes and has been implicated in the development of diffuse large B-cell lymphoma.